Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Chimerix Inc (CMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7977
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. It also develops active compounds against malaria, influenza A and B, brincidofovir for smallpox, dengue virus and tuberculosis, brincidofovir and adenovirus, among others. Chimerix’s lipid antiviral conjugate technology is used to modify a drug molecule order that it mimics a naturally occurring phospholipid metabolite. The company provides research and development services in the areas of CMV and BK virus, influenza, norovirus, and viruses that have significant global impact and there are currently no effective treatments, antivirals are associated with known toxicities such as bone marrow suppression and renal impairment. Chimerix is headquartered in Durham, North Carolina, the US.

Chimerix Inc (CMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Equity Offering 12
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc – Key Competitors 21
Chimerix Inc – Key Employees 22
Chimerix Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2018: Chimerix announces second quarter 2018 financial results 24
May 07, 2018: Chimerix Reports First Quarter 2018 Financial Results 26
Mar 01, 2018: Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results 28
Nov 08, 2017: Chimerix Announces Third Quarter 2017 Financial Results 30
Aug 07, 2017: Chimerix Announces Second Quarter 2017 Financial Results 32
May 09, 2017: Chimerix Announces First Quarter 2017 Financial Results 33
Mar 02, 2017: Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results 35
Corporate Communications 37
Mar 29, 2018: Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors 37
Product News 38
02/22/2017: Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings 38
Clinical Trials 39
Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Chimerix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc, Key Competitors 21
Chimerix Inc, Key Employees 22
Chimerix Inc, Subsidiaries 23

List of Figures
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Micron Technology Inc:戦略・SWOT・企業財務分析
    Micron Technology Inc - Strategy, SWOT and Corporate Finance Report Summary Micron Technology Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Rovsing AS:企業の戦略・SWOT・財務分析
    Rovsing AS - Strategy, SWOT and Corporate Finance Report Summary Rovsing AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • GlaxoSmithKline Plc (GSK)-医療機器分野:企業M&A・提携分析
    Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respira …
  • Banco Angolano de Investimentos, SA:企業の戦略・SWOT・財務情報
    Banco Angolano de Investimentos, SA - Strategy, SWOT and Corporate Finance Report Summary Banco Angolano de Investimentos, SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Construcciones y Auxiliar de Ferrocarriles SA:戦略・SWOT・企業財務分析
    Construcciones y Auxiliar de Ferrocarriles SA - Strategy, SWOT and Corporate Finance Report Summary Construcciones y Auxiliar de Ferrocarriles SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析
    Summary Heidelberg Pharma AG(Heidelberg Pharma) formerly known as Wilex AG is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small mo …
  • Nutra Pharma Corp (NPHC):企業の財務・戦略的SWOT分析
    Nutra Pharma Corp (NPHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Apollo Endosurgery Inc (APEN):医療機器:M&Aディール及び事業提携情報
    Summary Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company’s product portfolio comprises endo-bariatric products such as Orbera Intragastric Balloon System …
  • Swedish Match AB:企業の戦略・SWOT・財務情報
    Swedish Match AB - Strategy, SWOT and Corporate Finance Report Summary Swedish Match AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Clayton Homes Inc:企業の戦略・SWOT・財務情報
    Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report Summary Clayton Homes Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Richardson Electronics Ltd (RELL):企業の財務・戦略的SWOT分析
    Summary Richardson Electronics Ltd (Richardson Electronics) is a technology company that carries out manufacturing of electron tube. The company offers engineered solutions, power grid and microwave tubes and consumables, displays, flat panel detector solutions and parts for diagnostic imaging equip …
  • Hascol Petroleum Ltd (HASCOL):石油・ガス:M&Aディール及び事業提携情報
    Summary Hascol Petroleum Ltd (Hascol) is a petroleum product distributor. The company offers products such as rocket diesel, gasoline, fuel oil, tiger super and furnace oil, and FUCHS lubricants. Its FUCHS lubricants include corrosion preventives, quenching oils, industrial lube, industrial lube, sp …
  • McEwen Mining Inc.:企業の戦略・SWOT・財務情報
    McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report Summary McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Twist Bioscience Corp (TWST):製薬・医療:M&Aディール及び事業提携情報
    Summary Twist Bioscience Corp (Twist Bioscience) is a provider of synthetic DNA Tools. Its silicon-based DNA synthesis platform enables precise synthesis and sequencing process and production of synthetic DNA tools. The company offers its products which include DNA tools for gRNA cloning such as una …
  • Bunzl plc (BNZL)-医療機器分野:企業M&A・提携分析
    Summary Bunzl plc (Bunzl) is a global distribution and outsourcing company that supplies a broad range of non-food products to a diverse market sectors. The company offers an array of food packaging, disposable tableware and catering equipment, cleaning and hygiene supplies, guest amenities, persona …
  • Oil and Natural Gas Corporation Ltd (ONGC)-エネルギー分野:企業M&A・提携分析
    Summary Oil and Natural Gas Corporation Ltd (ONGC) is an integrated oil and gas company. It explores for and produces oil and natural gas; refines crude oil; and markets and distributes petroleum products. The company's product portfolio includes crude oil, natural gas, liquefied natural gas, naphth …
  • Smiths Group plc:企業の戦略・SWOT・財務情報
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Brunei National Petroleum Company Sendirian Berhad:石油・ガス:M&Aディール及び事業提携情報
    Summary Brunei National Petroleum Company Sendirian Berhad (PetroleumBRUNEI) is an oil and gas company that provides exploration and production of oil and gas. The company offers engineering, procurement, construction, installation, commissioning services, and others. It provides oilfield services, …
  • Italian Coffee Holdings Ltd:企業の戦略・SWOT・財務分析
    Italian Coffee Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Italian Coffee Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Celsia SA ESP (CELSIA):企業の財務・戦略的SWOT分析
    Summary Celsia SA ESP (Celsia), formerly Compania Colombiana de Inversiones SA ESP, a subsidiary of Grupo Argos SA, is an energy company that generates, transmits, distributes, and sells electricity. The company’s product categories include home line, solar energy, backup energy, thermal network, ef …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆